Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

Sarepta Therapeutics (SRPT) stock plunged over 40% after Reuters reported the FDA plans to request a voluntary halt to shipments of its gene therapy, Elevidys, following multiple patient deaths from acute liver failure. This intensified regulatory scrutiny, compounded by concerns over management's delayed disclosure of a third fatality, significantly impacts the company's outlook and raises questions regarding the therapy's market viability and patient confidence.

Analysis

Sarepta Therapeutics (SRPT) is facing a severe crisis driven by a confluence of regulatory, safety, and governance issues. The stock's precipitous fall of over 40% to a nine-year low directly reflects a Reuters report that the FDA intends to request a voluntary halt on all shipments of its key gene therapy, Elevidys. This regulatory pressure stems from critical safety signals, specifically the deaths of three patients from acute liver failure after receiving Sarepta's gene therapies. The shared adeno-associated virus (AAV) vector used in both Elevidys and the experimental SRP-9004 links these adverse events, amplifying concerns about the core technology platform and potentially increasing patient hesitancy. Compounding this is a significant blow to management's credibility, as analysts have pointedly questioned the delayed disclosure of the third patient death, which the CEO described as not "material" to a recent restructuring announcement. This raises concerns about transparency and the true rationale behind the company's recent layoffs and program cuts, which were initially attributed solely to financial reasons.

Key Decisions for Investors

• Investors should recognize the extremely high-risk profile of SRPT, as the potential FDA-requested sales halt for its cornerstone product, Elevidys, combined with a severe erosion in management credibility, presents a significant threat to the company's valuation and viability.
• Closely monitor for official communications from both the FDA and Sarepta regarding the status of Elevidys shipments and the specifics of the pending label change, as these events will be the primary drivers of the stock's trajectory.
• Exercise extreme caution before considering the 40% stock decline a buying opportunity, as the fundamental outlook is clouded by the binary risk of regulatory action and the challenge of rebuilding trust with both the medical community and investors.